ABBOTT LABORATORIES Insider Trading for April 2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ABBOTT LABORATORIES.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ABBOTT LABORATORIES for April 2020.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 30 2020 | ABT | ABBOTT LABORATORIE ... | WOODGRIFT RANDEL WILLIAM | Senior Vice Preside ... | Sell | S | 93.18 | 3,724 | 347,012 | 48,767 | 52.5 K to 48.8 K (-7.09 %) |
Apr 28 2020 | ABT | ABBOTT LABORATORIE ... | TILTON GLENN F | Director | Grant | A | 0.00 | 1,974 | 0 | 43,027 | 41.1 K to 43 K (+4.81 %) |
Apr 28 2020 | ABT | ABBOTT LABORATORIE ... | Stratton John G | Director | Grant | A | 0.00 | 1,974 | 0 | 10,615 | 8.6 K to 10.6 K (+22.84 %) |
Apr 28 2020 | ABT | ABBOTT LABORATORIE ... | STARKS DANIEL J | Director | Grant | A | 0.00 | 1,974 | 0 | 7,020,399 | 7 M to 7 M (+0.03 %) |
Apr 28 2020 | ABT | ABBOTT LABORATORIE ... | OSBORN WILLIAM A | Director | Option Exercise | A | 93.68 | 9,991 | 935,957 | 9,991 | |
Apr 28 2020 | ABT | ABBOTT LABORATORIE ... | OSBORN WILLIAM A | Director | Grant | A | 0.00 | 1,974 | 0 | 58,297 | 56.3 K to 58.3 K (+3.50 %) |
Apr 28 2020 | ABT | ABBOTT LABORATORIE ... | NOVAKOVIC PHEBE N | Director | Option Exercise | A | 93.68 | 9,030 | 845,930 | 9,030 | |
Apr 28 2020 | ABT | ABBOTT LABORATORIE ... | NOVAKOVIC PHEBE N | Director | Grant | A | 0.00 | 1,974 | 0 | 28,307 | 26.3 K to 28.3 K (+7.50 %) |
Apr 28 2020 | ABT | ABBOTT LABORATORIE ... | McKinstry Nancy | Director | Option Exercise | A | 93.68 | 8,454 | 791,971 | 8,454 | |
Apr 28 2020 | ABT | ABBOTT LABORATORIE ... | McKinstry Nancy | Director | Grant | A | 0.00 | 1,974 | 0 | 25,640 | 23.7 K to 25.6 K (+8.34 %) |
Apr 28 2020 | ABT | ABBOTT LABORATORIE ... | McDew Darren W | Director | Grant | A | 0.00 | 1,974 | 0 | 1,974 | 0 to 2 K |
Apr 28 2020 | ABT | ABBOTT LABORATORIE ... | LIDDY EDWARD M | Director | Option Exercise | A | 93.68 | 9,671 | 905,979 | 9,671 | |
Apr 28 2020 | ABT | ABBOTT LABORATORIE ... | LIDDY EDWARD M | Director | Grant | A | 0.00 | 1,974 | 0 | 30,127 | 28.2 K to 30.1 K (+7.01 %) |
Apr 28 2020 | ABT | ABBOTT LABORATORIE ... | Kumbier Michelle | Director | Grant | A | 0.00 | 1,974 | 0 | 5,248 | 3.3 K to 5.2 K (+60.29 %) |
Apr 28 2020 | ABT | ABBOTT LABORATORIE ... | Blount Sally E. | Director | Grant | A | 0.00 | 1,974 | 0 | 28,240 | 26.3 K to 28.2 K (+7.52 %) |
Apr 28 2020 | ABT | ABBOTT LABORATORIE ... | AUSTIN ROXANNE S | Director | Option Exercise | A | 93.68 | 9,735 | 911,975 | 9,735 | |
Apr 28 2020 | ABT | ABBOTT LABORATORIE ... | AUSTIN ROXANNE S | Director | Grant | A | 0.00 | 1,974 | 0 | 46,887 | 44.9 K to 46.9 K (+4.40 %) |
Apr 28 2020 | ABT | ABBOTT LABORATORIE ... | Alpern Robert J | Director | Grant | A | 0.00 | 1,974 | 0 | 32,380 | 30.4 K to 32.4 K (+6.49 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Ginascol John F | Executive Vice Pres ... | Option Exercise | M | 38.40 | 63,200 | 2,426,880 | 20,133 | |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Ginascol John F | Executive Vice Pres ... | Sell | S | 96.26 | 39,234 | 3,776,630 | 66,445 | 105.7 K to 66.4 K (-37.13 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Ginascol John F | Executive Vice Pres ... | Sell | S | 95.57 | 23,966 | 2,290,421 | 105,679 | 129.6 K to 105.7 K (-18.49 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Ginascol John F | Executive Vice Pres ... | Buy | M | 38.40 | 63,200 | 2,426,880 | 129,645 | 66.4 K to 129.6 K (+95.12 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | CAPEK JOHN M | Executive Vice Pres ... | Option Exercise | M | 22.39 | 50,100 | 1,121,834 | 0 | |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | CAPEK JOHN M | Executive Vice Pres ... | Sell | S | 96.28 | 18,701 | 1,800,596 | 316,800 | 335.5 K to 316.8 K (-5.57 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | CAPEK JOHN M | Executive Vice Pres ... | Sell | S | 95.63 | 31,399 | 3,002,730 | 335,501 | 366.9 K to 335.5 K (-8.56 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | CAPEK JOHN M | Executive Vice Pres ... | Buy | M | 22.39 | 50,100 | 1,121,834 | 366,900 | 316.8 K to 366.9 K (+15.81 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Scoggins Christopher J | Senior Vice Preside ... | Sell | S | 96.10 | 414 | 39,785 | 39,706 | 40.1 K to 39.7 K (-1.03 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Ginascol John F | Executive Vice Pres ... | Option Exercise | M | 38.40 | 63,200 | 2,426,880 | 20,133 | |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Funck Robert E | Executive Vice Pres ... | Option Exercise | M | 39.12 | 13,000 | 508,560 | 31,325 | |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Ginascol John F | Executive Vice Pres ... | Sell | S | 96.26 | 39,234 | 3,776,630 | 66,445 | 105.7 K to 66.4 K (-37.13 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Funck Robert E | Executive Vice Pres ... | Option Exercise | M | 34.94 | 23,700 | 828,078 | 0 | |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Ginascol John F | Executive Vice Pres ... | Sell | S | 95.57 | 23,966 | 2,290,421 | 105,679 | 129.6 K to 105.7 K (-18.49 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Funck Robert E | Executive Vice Pres ... | Payment of Exercise | F | 98.00 | 23,855 | 2,337,790 | 182,217 | 206.1 K to 182.2 K (-11.58 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Ginascol John F | Executive Vice Pres ... | Buy | M | 38.40 | 63,200 | 2,426,880 | 129,645 | 66.4 K to 129.6 K (+95.12 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Funck Robert E | Executive Vice Pres ... | Buy | M | 39.12 | 13,000 | 508,560 | 206,072 | 193.1 K to 206.1 K (+6.73 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | CAPEK JOHN M | Executive Vice Pres ... | Option Exercise | M | 22.39 | 50,100 | 1,121,834 | 0 | |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Funck Robert E | Executive Vice Pres ... | Buy | M | 34.94 | 23,700 | 828,078 | 193,072 | 169.4 K to 193.1 K (+13.99 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | CAPEK JOHN M | Executive Vice Pres ... | Sell | S | 96.28 | 18,701 | 1,800,596 | 316,800 | 335.5 K to 316.8 K (-5.57 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | CAPEK JOHN M | Executive Vice Pres ... | Sell | S | 95.63 | 31,399 | 3,002,730 | 335,501 | 366.9 K to 335.5 K (-8.56 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | CAPEK JOHN M | Executive Vice Pres ... | Buy | M | 22.39 | 50,100 | 1,121,834 | 366,900 | 316.8 K to 366.9 K (+15.81 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Scoggins Christopher J | Senior Vice Preside ... | Sell | S | 96.10 | 414 | 39,785 | 39,706 | 40.1 K to 39.7 K (-1.03 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Funck Robert E | Executive Vice Pres ... | Option Exercise | M | 39.12 | 13,000 | 508,560 | 31,325 | |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Funck Robert E | Executive Vice Pres ... | Option Exercise | M | 34.94 | 23,700 | 828,078 | 0 | |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Funck Robert E | Executive Vice Pres ... | Payment of Exercise | F | 98.00 | 23,855 | 2,337,790 | 182,217 | 206.1 K to 182.2 K (-11.58 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Funck Robert E | Executive Vice Pres ... | Buy | M | 39.12 | 13,000 | 508,560 | 206,072 | 193.1 K to 206.1 K (+6.73 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Funck Robert E | Executive Vice Pres ... | Buy | M | 34.94 | 23,700 | 828,078 | 193,072 | 169.4 K to 193.1 K (+13.99 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Contreras Jaime | Senior Vice Preside ... | Option Exercise | M | 75.90 | 25,681 | 1,949,188 | 51,364 | |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Contreras Jaime | Senior Vice Preside ... | Option Exercise | M | 59.94 | 36,715 | 2,200,697 | 36,715 | |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Contreras Jaime | Senior Vice Preside ... | Option Exercise | M | 44.40 | 46,016 | 2,043,110 | 0 | |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Contreras Jaime | Senior Vice Preside ... | Payment of Exercise | F | 98.00 | 83,226 | 8,156,148 | 62,205 | 145.4 K to 62.2 K (-57.23 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Contreras Jaime | Senior Vice Preside ... | Buy | M | 75.90 | 25,681 | 1,949,188 | 145,431 | 119.8 K to 145.4 K (+21.45 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Contreras Jaime | Senior Vice Preside ... | Buy | M | 59.94 | 36,715 | 2,200,697 | 119,750 | 83 K to 119.8 K (+44.22 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Contreras Jaime | Senior Vice Preside ... | Buy | M | 44.40 | 46,016 | 2,043,110 | 83,035 | 37 K to 83 K (+124.30 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Contreras Jaime | Senior Vice Preside ... | Option Exercise | M | 75.90 | 25,681 | 1,949,188 | 51,364 | |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Contreras Jaime | Senior Vice Preside ... | Option Exercise | M | 59.94 | 36,715 | 2,200,697 | 36,715 | |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Contreras Jaime | Senior Vice Preside ... | Option Exercise | M | 44.40 | 46,016 | 2,043,110 | 0 | |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Contreras Jaime | Senior Vice Preside ... | Payment of Exercise | F | 98.00 | 83,226 | 8,156,148 | 62,205 | 145.4 K to 62.2 K (-57.23 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Contreras Jaime | Senior Vice Preside ... | Buy | M | 75.90 | 25,681 | 1,949,188 | 145,431 | 119.8 K to 145.4 K (+21.45 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Contreras Jaime | Senior Vice Preside ... | Buy | M | 59.94 | 36,715 | 2,200,697 | 119,750 | 83 K to 119.8 K (+44.22 %) |
Apr 23 2020 | ABT | ABBOTT LABORATORIE ... | Contreras Jaime | Senior Vice Preside ... | Buy | M | 44.40 | 46,016 | 2,043,110 | 83,035 | 37 K to 83 K (+124.30 %) |
Apr 03 2020 | ABT | ABBOTT LABORATORIE ... | WOODGRIFT RANDEL WILLIAM | Senior Vice Preside ... | Payment of Exercise | F | 78.91 | 1,368 | 107,949 | 52,491 | 53.9 K to 52.5 K (-2.54 %) |
Apr 03 2020 | ABT | ABBOTT LABORATORIE ... | Scoggins Christopher J | Senior Vice Preside ... | Payment of Exercise | F | 78.91 | 1,048 | 82,698 | 40,120 | 41.2 K to 40.1 K (-2.55 %) |
Apr 03 2020 | ABT | ABBOTT LABORATORIE ... | LANE ANDREW H | Executive Vice Pres ... | Payment of Exercise | F | 78.91 | 365 | 28,802 | 65,822 | 66.2 K to 65.8 K (-0.55 %) |
Apr 03 2020 | ABT | ABBOTT LABORATORIE ... | LANE ANDREW H | Executive Vice Pres ... | Grant | A | 0.00 | 1,659 | 0 | 66,187 | 64.5 K to 66.2 K (+2.57 %) |
Apr 02 2020 | ABT | ABBOTT LABORATORIE ... | Stratton John G | Director | Option Exercise | A | 0.00 | 399 | 0 | 5,069 | |
Apr 02 2020 | ABT | ABBOTT LABORATORIE ... | Alpern Robert J | Director | Option Exercise | A | 0.00 | 99 | 0 | 7,897 | |
Apr 01 2020 | ABT | ABBOTT LABORATORIE ... | Contreras Jaime | Senior Vice Preside ... | Payment of Exercise | F | 79.34 | 343 | 27,214 | 2,624 | 3 K to 2.6 K (-11.56 %) |
Apr 01 2020 | ABT | ABBOTT LABORATORIE ... | Contreras Jaime | Senior Vice Preside ... | Grant | A | 0.00 | 740 | 0 | 2,967 | 2.2 K to 3 K (+33.23 %) |